ArticleFrontiers in cardiovascular medicine2025
Efficacy of embolo/sclerotherapy in the treatment of high-output cardiac failure caused by peripheral arteriovenous malformations.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the effectiveness and outcomes of embolo/sclerotherapy in treating Schobinger Stage IV peripheral arteriovenous malformations (pAVMs) associated with high-output cardiac failure (HOCF). Methods: Between January 2017 and December 2024, 12 patients with Schobinger Stage IV pAVMs and associated HOCF were treated with embolization using coils and sclerosing agents, including bleomycin polidocanol foam (BPF) and anhydrous ethanol. Procedural outcomes, complications, devascularization and improvements in cardiac function were evaluated during follow-up. Results: A total of 24 embolo/sclerotherapy sessions were performed on the 12 patients. Complete or over 80% devascularization of the vascular malformations was achieved in 9 patients. Echocardiographic follow-up revealed significant improvements in cardiac ejection fraction and ventricular dilatation. Additionally, 8 patients showed improvement in heart valve regurgitation. For all patients, the symptom of dyspnea disappeared after embolization and no serious complications occurred. LVEF improvement showed a significant positive correlation with a decrease in venous drainage pressure of the nidus after surgery ( Conclusion: This study provides evidence that embolo/sclerotherapy effectively treats pAVMs with associated HOCF by reducing abnormal blood flow and significantly improving symptoms. The results also reveal a linear relationship between the decrease in venous drainage pressure and improvement in LVEF in patients with HOCF caused by pAVMs after embolo/sclerotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.